Secondary Amyloidosis Development in a Patient with Juvenile Rheumatoid Arthritis on TNF-alpha Inhibitors Treatment.
10.4078/jrd.2012.19.5.280
- Author:
Hong Ki MIN
1
;
Moon Hee YOON
;
Eun Oh KIM
;
Dae Won KIM
;
Nam Yong KIM
;
Seung Ki KWOK
;
Sung Hwan PARK
;
Ho Youn KIM
;
Ji Hyeon JU
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. juji@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
TNF-alpha inhibitor;
Rheumatoid arthritis;
Amyloidosis
- MeSH:
Adult;
Amyloid;
Amyloidosis;
Arthritis, Juvenile Rheumatoid;
Arthritis, Rheumatoid;
Humans;
Tumor Necrosis Factor-alpha
- From:Journal of Rheumatic Diseases
2012;19(5):280-284
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Secondary amyloidosis is one of the most serious complications in chronic inflammatory diseases such as rheumatoid arthritis. The extracellular deposit of aggregates of amyloid leads to target organ dysfunction. The mainstay treatment of secondary amyloidosis is the control of underlying disease activity. Many reports have reported that TNF-alpha inhibitors improve clinical outcomes. Here, we encountered a 34-year-old patient with juvenile rheumatoid arthritis who developed secondary amyloidosis despite treatment with TNF-alpha inhibitors. We present this case and include a review of the literature.
